Noxopharm Limited
Noxopharm Limited (NOXOF) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Noxopharm Limited (NOXOF), covering cash flow, earnings, and balance sheets.
Noxopharm Limited (NOXOF) Income Statement & Financial Overview
View the income breakdown for Noxopharm Limited NOXOF across both annual and quarterly reports.
| Metric | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 |
|---|---|---|---|---|
| Revenue | $1.16M | $1.19M | $1.21M | $1.33M |
| Cost of Revenue | $1.55M | $1.48M | $876.00 | $11041.00 |
| Gross Profit | -$394530.00 | -$295752.00 | $1.21M | $1.32M |
| Gross Profit Ratio | -$0.34 | -$0.25 | $1.00 | $0.99 |
| R&D Expenses | $1.55M | $1.48M | $1.45M | $4.85M |
| SG&A Expenses | $1.86M | $2.05M | $2.02M | $2.76M |
| Operating Expenses | $3.41M | $3.53M | $3.47M | $7.62M |
| Total Costs & Expenses | $4.97M | $5.01M | $3.47M | $7.63M |
| Interest Income | $0.00 | $24.00 | $6906.00 | $18596.00 |
| Interest Expense | $0.00 | $4663.00 | $26497.00 | $33388.00 |
| Depreciation & Amortization | $879.00 | $867.00 | $876.00 | $11041.00 |
| EBITDA | -$2.26M | -$2.34M | -$3.68M | -$2.51M |
| EBITDA Ratio | -$1.95 | -$1.97 | -$3.04 | -$5.72 |
| Operating Income | -$3.81M | -$3.83M | -$3.47M | -$7.63M |
| Operating Income Ratio | -$3.29 | -$3.22 | -$2.86 | -$5.73 |
| Other Income/Expenses (Net) | $1.42M | $1.56M | -$1033.00 | -$4.67M |
| Income Before Tax | -$2.39M | -$2.27M | -$3.71M | -$12.29M |
| Income Before Tax Ratio | -$2.07 | -$1.91 | -$3.06 | -$9.23 |
| Income Tax Expense | -$1.16M | -$1.19M | -$1.21M | -$2.66M |
| Net Income | -$1.24M | -$1.08M | -$2.50M | -$9.63M |
| Net Income Ratio | -$1.07 | -$0.91 | -$2.06 | -$7.23 |
| EPS | -$0.004 | -$0.004 | -$0.009 | -$0.03 |
| Diluted EPS | -$0.004 | -$0.004 | -$0.009 | -$0.03 |
| Weighted Avg Shares Outstanding | $292.29M | $292.02M | $292.24M | $292.24M |
| Weighted Avg Shares Outstanding (Diluted) | $292.24M | $292.24M | $292.24M | $292.24M |
Over the last four quarters, Noxopharm Limited's revenue moved from $1.33M in Q4 2023 to $1.16M in Q2 2025. Operating income in Q2 2025 was -$3.81M, with a strong operating margin of -329%. Despite fluctuations in R&D and SG&A expenses, EBITDA for Noxopharm Limited remained robust at -$2.26M, reflecting operational efficiency. Net income dropped to -$1.24M, with an EPS of -$0.004. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan